EVOFLOXACIN PREVENTS FEBRILE NEUTROPENIA DURING CYTARABINE CONSOLIDATION (IDAC/HIDAC) IN ACUTE MYELOID LEUKEMIA
Phase 3
Completed
- Conditions
- We aimed to evaluate the efficacy of levofloxacin for febrile neutropenia prevention following cytarabine containing consolidation chemotherapy (intermediate dose-IDAC or high dose-HIDAC) in newly diagnosed AML patients.AML , febrile neutropenia, levofloxacin
- Registration Number
- TCTR20240401009
- Lead Sponsor
- none
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Aged 18-65 years old
Newly diagnosed AML S/P IDAC/HIDAC From Jan 2021 to Dec 2023
Accept Informed consent
Exclusion Criteria
Rate of hospital admission due to febrile neutropenia
Length of hospital stay due to febrile neutropenia
Culture-positive bacteremia rate
Composite outcome of septic shock rate and infectious-related mortality
Side effects of levofloxacin
Clostridium difficile-associated disease in 30 days after taking levofloxacin
Fluoroquinolone resistance organism
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinically documented Febrile neutropenia 120 days number of patients
- Secondary Outcome Measures
Name Time Method Rate of hospital admission due to febrile neutropenia 120 days days